Pipeline
GlioCART is building a pipeline of next-generation CAR-T therapies targeting both the tumor and its immunosuppressive microenvironment.
With a focused lead program in glioblastoma and a scalable platform approach, we aim to address high unmet need across solid tumors.
Lead Program: EGFRvIII-SGRP
GlioCART’s lead candidate, EGFRvIII-SGRP, is advancing toward clinical development in glioblastoma. The program is designed to deliver a dual-action CAR-T therapy targeting both tumor cells and the immunosuppressive microenvironment.
Targeting first-in-human data Q1 2027 and Phase IIa completion by 2029
Expanding the Platform
GlioCART is building a pipeline of next-generation CAR-T therapies targeting both tumor cells and the immunosuppressive microenvironment.
This dual-action strategy is supported by validation in established CAR-T systems and enables expansion beyond glioblastoma into additional high-need solid tumor indications.
